Congenital hypertrophy of retinal pigment epithelium (CHRPE) in patients with familial adenomatous polyposis (FAP); a polyposis registry experience by Anwer Nusliha et al.
Nusliha et al. BMC Research Notes 2014, 7:734
http://www.biomedcentral.com/1756-0500/7/734SHORT REPORT Open AccessCongenital hypertrophy of retinal pigment
epithelium (CHRPE) in patients with familial
adenomatous polyposis (FAP); a polyposis registry
experience
Anwer Nusliha1, Ushantha Dalpatadu1, Binara Amarasinghe1, Pramodh Chitral Chandrasinghe2
and Kemal Ismail Deen2*Abstract
Background: Familial Adenomatous Polyposis (FAP) is an autosomal dominant condition giving rise to multiple
adenomatous polyps in the colon which invariably become malignant by the fourth decade. Congenital
hypertrophy of retinal pigment epithelium (CHRPE) is one of its extra intestinal manifestations early in childhood
seen, present in 90% of FAP population and is easy to detect.
Findings: Patients diagnosed with FAP and at risk first degree family members were screened for CHRPE using a slit
lamp and indirect ophthalmoscopy. The retina of 17 diagnosed FAP patients and 13 individuals at risk were examined.
The site and size of CHRPE lesions were documented. Thirteen (76%) of 17 FAP patients (male-10, female – 7, median
age - 30 years; range 15-55 years) had CHRPE lesions; seven (54%) had bilateral CHRPE lesions and six (46%) had
unilateral lesions. A single lesion was detected in 6 (46%) while 7 (54%) patients had multiple lesions. Of 13 at risk
individuals (7- male, female-6 ; median age 34; range 16-52 years), one was positive for CHRPE and 12 were free
of retinal lesions. The sensitivity of the presence of a CHRPE lesion in association with colonic polyps in FAP was
76%, specificity 92%, positive predictive value 93%, and negative predictive value 75%.
Conclusions: This study found a high sensitivity and specificity for a CHRPE lesion to be associated with colonic
polyps of FAP and hence a useful screening method in a burdened health-care system. The method is minimally
invasive and simple and would be of particular value in screening children at risk for FAP.
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Familial adenomatous polyposis (FAP) is a genetic dis-
order transmitted in an autosomal dominant pattern [1,2].
Patients develop multiple adenomatous polyps in the
colon varying from a hundred to thousands in number. If
left, these polyps will invariably transform, through the
adenoma-carcinoma sequence, to colorectal malignancy
[3-5]. Therefore early diagnosis and appropriate treatment
is essential. Patients may develop extra intestinal manifes-
tations such as congenital hypertrophy of retinal pigment
epithelium (CHRPE), sebaceous cysts (51%), desmoids* Correspondence: radihan@mail.ewisl.net
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unless otherwise stated.tumours (26%), and in lesser proportions, osteomas, lip-
omas (Gardner’s syndrome ) and extra intestinal malig-
nancies; hepatomas, retinoblastomas and brain tumours
(Turcot’s syndrome) [6-9]. FAP is also associated with the
presence of polyps in the upper gastro intestinal tract in
90 to 100 percent [7,8]. Familial adenomatous polyposis is
caused by mutations in the adenomatous polyposis coli
(APC) gene, a tumour suppressor gene, located in the long
arm of chromosome 5 [10-12]. The condition is auto-
somal dominant making half of the off spring of an af-
fected individual parent at risk of developing FAP [10,11].
Disease has a hundred percent penetrance when the geno-
type is present. FAP related CHRPE may not be seen in all
with the FAP genotype. For example, mutations in codonLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and absent CHRPE [13]. CHRPE was first described by
Blair and Trempe in 1980 [8]. It is commonly caused by a
truncating mutation in the codons between 463 and 1387
of the APC gene [14-19]. The global prevalence of CHRPE
in individuals with the APC mutation is ninety percent
[9]. This makes detection of CHRPE in asymptomatic in-
dividuals who are at risk an attractive screening option. It
is the most common and earliest extra colonic manifest-
ation amongst FAP populations which may be present at
birth (80%) or shortly after birth [8,15,16]. It is a darkly
pigmented lesion with a depigmented halo in the retina
[17]. It may be single or multiple, unilateral or bilateral.
The size of a CHRPE lesion is variable but most are simi-
lar in diameter to the optic disc [20]. Lesions may be oval,
round or bean shaped. Oval CHRPE lesions with fishtail
shaped hypo-pigmented change at one or both ends may
be associated with FAP [21]. CHRPE has no malignant po-
tential [22]. The prevelance of CHRPE in the normal
population is between 1.2% to 4.4% [23] which increases
its specificity for screening. The aim of our study was to
assess the value of ophthalmic screening, to find the asso-
ciation of CHRPE lesions in individuals with FAP or their
family members in a local population and to describe the
pattern of distribution of CHRPE lesions in these individ-
uals in order to assess the feasibility of using it as a low
cost, non invasive screening test to detect FAP.
Findings
Material and method
All individuals with a diagnosis of familial adenomatous
polyposis made at the professorial surgical unit, Ragama
between 1996 and 2010, were traced using clinical notes,
endoscopic registers and admission books. Proformas
were prepared for FAP patients and relatives at risk. The
proforma contained all details about the patient includ-
ing a plan of follow up. All FAP patients and individuals
at risk were invited for registration in the FAP registry.
A consent form was prepared in three languages (Sin-
hala, English and Tamil) and informed written consent
was taken from all individuals participating in the activ-
ities of the registry. Those who consented were sub-
jected to ophthalmological screening.
Ophthalmological examination was performed by an
experienced ophthalmologist at North Colombo Teach-
ing Hospital, Ragama. In all individuals, the eyes were
checked for visual acuity as screening, followed by dila-
tation of the pupils using tropicamide and phenylephrine
ophthalmic solution. After the pupils were fully dilated,
slit lamp and indirect ophthalmoscopic examinations
were performed to identify CHRPE lesions. If found, the
site, size, number and shape of lesions were documented.
A common side effect of this procedure was transient
blurring of vision, which reversed in a few hours. Thosewho had ophthalmological screening for CHRPE lesions
underwent a flexible sigmoidoscopy to look for the pres-
ence of polyps in the colon. If they were found to have
polyps in the colon, an upper gastro intestinal endoscopy
was also performed to look for polyps in the stomach and
duodenum which may have malignant potential. Data
were analyzed using the Statistical Package for Social Sci-
ence version 17.0 (SPSS 17.0, Chicago, Illinois, USA). The
sensitivity, specificity, positive predictive value and nega-
tive predictive value of CHRPE lesions in FAP and those
at risk were calculated. Ethical clearance was obtained
from the National Research Council, Sri Lanka and the
Ethics Review Committee of University of Kelaniya med-
ical school at Ragama.
Results
Seventeen diagnosed patients (male-10, female-7, me-
dian age- 30 years, range 15-55 years) with FAP and 13
individuals at risk (male-7, female-6, median age -34,
range 16-52 years) were screened by an ophthalmologist.
Of those with FAP, 13 (76%) were positive for CHRPE
and 4 (24%) were negative. Six (46%) had a unilateral le-
sion and 7 (54%) had bilateral lesions. A solitary lesion
in 6 (46%) and multiple lesions in the same eye were
found in 7 (54%) patients. CHRPE lesions were either
round or oval in shape. Of 13 individuals at risk, one
had a single and large CHRPE lesion in one eye. Cur-
rently he does not have polyps in the colon and he is
under surveillance for colonic and upper intestinal
polyps. The remaining 12 were negative for both CHRPE
in the retina and polyps in the colon. Response rate
amongst affected individuals was 68% (17 out of 25
reponded) and the at risk population was 32% (13 out of
40). The sensitivity of CHRPE as a screening test for the
presence of FAP is 76% (95% CI : 0.56 - 0.97) and the
specificity is 92% (95% CI: 0.78 - 1.07). The positive pre-
dictive value is 93% (95% CI: 0.79 - 1.06) while the nega-
tive predictive value is 75% (95% CI: 0.54 - 0.96).
Discussion
FAP is a genetic disorder which accounts for 1% of colo-
rectal cancer [2,3,6]. Almost all patients develop colorec-
tal cancer from adenomatous polyps unless detected
early and managed by prophylactic removal of the colon
and rectum. Therefore, early diagnosis is paramount.
Currently the standard surgical treatment for FAP is re-
storative proctocolectomy with ileal pouch anal anasto-
mosis. As CHRPE is one of the commonest and earliest
extra intestinal manifestations, it lends itself as a screen-
ing tool for family members of FAP patients. The sensi-
tivity of CHRPE in our study is 76% and it is comparable
with other studies [17]. Chen CS et al reported 56% sen-
sitivity in detecting FAP with CHRPE while none of the
subjects with hereditary non polyposis colon cancer in
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present in FAP patients may not be CHRPE. These may
be harmatomatous lesions which will be difficult to dif-
ferentiate without special imaging techniques such as
spectral-domain optical coherence tomography [24]. A
drawback in our study was that ‘at risk’ individuals were
assessed with endoscopy and not genetic studies. Some
of these patients may have the genotype which is yet to
manifest clinically. Although genetic testing is precise in
most settings sigmoidoscopy is accepted as a screening
tool due to financial constraints. We found that screen-
ing for CHRPE was relatively easy and caused minimum
discomfort to the individual. Compared with colonos-
copy, retinal screening seems more acceptable and less
stigmatic. The examination is safe and repeatable. Al-
though we did not study the cost benefit of retinal
screening, it is our impression that retinal screening
is less expensive compared with colonoscopy. Once
CHRPE lesions are detected the screening of family
members at risk could be intensified and should be done
in a coordinated manner under the guidance of an FAP
Registry. CHRPE detection can also help to persuade in-
dividuals at risk for regular follow up and improve their
compliance. In Sri Lanka, financial constraints hinder
genetic testing; screening for CHRPE will be most ap-
propriate and invaluable to diagnose FAP. Furthermore,
it may be suggested that CHRPE positivity will allow tar-
geted genetic screening.
Conclusions
Screening for CHRPE is an easy, simple to perform, non
invasive, safe and reproducible method of diagnosing
FAP. As shown in this study it can be used as an effect-
ive first-line screening method for FAP. In conjunction
with other screening methods it is invaluable in early
diagnosis of FAP patients. As patients’ compliance is
good with this screening method we could screen many
patients who are at risk for FAP enabling early and ap-
propriate management for those with FAP.
Abbreviations
CHRPE: Congenital hypertrophy of retinal pigment epithelium; FAP: Familial
adenomatous polyposis coli.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AN, UD were involved in data collection, analysis and preparation of the
manuscript. BA was involved in performing ophthalmic screening and
critically appraising the manuscript. UD, PCC and KID were involved in
patient management, data interpretation and appraising the manuscript.
All authors read and approved the final manuscript.
Acknowledgement
The authors wish to thank DNU Jayathunga and D Pinto for their services in
data collection analysis and coordination of the study. We declare that none
of the authors received funding of what so ever from any organisation or
individual for carrying out the research.Author details
1North Colombo Teaching Hospital, Ragama, Sri Lanka. 2Faculty of Medicine,
University of Kelaniya, Ragama, Sri Lanka.
Received: 22 March 2014 Accepted: 10 October 2014
Published: 18 October 2014
References
1. Cambell WJ, Spence RA, Parks TG: Familial adenomatous polyposis. BJS
1994, 81:1722–1733.
2. Nieuwenhuis MH, Vasen HF: Correlations between mutation site in APC
and phenotype of familial adenomatous polyposis (FAP): a review of the
literature. Crit Rev Oncol Hematol 2007, 61:153–161.
3. Cambel WJ, Spence RAJ, Parks TG: The role of congenital hypertrophy of
the retinal pigment epithelium in screening for familial adenomatous
polyposis. Int J Colorectal Dis 2004, 9:191–196.
4. Iwama T, Mishima Y, Okamano N, Inoue J: Association of congenital
hypertrophy of the retinal pigment epithelium with familial
adenomatous polyposis. BJS 2005, 77:273–276.
5. Bisgaard ML, Bulow S: Familial adenomatous polyposis (FAP): genotype
correlation to FAP phenotype with osteomas and sebaceous cysts. Am J
Med Gene 2006, 140:200–204.
6. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J
Rare Dis 2009, 4:22.
7. Baker RH, Heinemann MH, Miller MH, DeCosse JJ: Hyper-pigment lesions of
the retinal pigment epithelium in familial adenomatous polyposis. Am J
Med Gene 2005, 31:427–435.
8. Traboulsi ET, Maumenee IH, Krush AJ, Alcorn D, Giardiello FM, Burt RW,
Hughes JP, Hamilton SR: Congenital hypertrophy of the retinal pigment
epithelium predicts colorectal polyps in Gardner’s syndrome. BMJ 1989,
298:353.
9. Wallis YL, Macdonald F, Hulten M, Morton JEV, Mckeown M, Neoptolemos
JP, Keighley M, Morton DG: Genotype- Phenotype correlation between
position of constitutional APC gene mutation and CHRPE expressed in
FAP. Hum Gene 1994, 94:543–548.
10. Takahashi M, Kikuchi M, Ohkura N, Yaguchi H, Nagamura Y, Ohnami S,
Ushiama M, Yoshida T, Sugano K, Iwama T, Kosugi S, Tsukada T: Detection
of APC gene deletion by double competitive polymerase chain reaction in
patients with familial adenomatous polyposis. Int J Oncol 2006, 29:413–421.
11. Zajac V, Kovac M, Kirchhoff T, Stevurkova V, Tomka M: The most frequent
APC mutations among Slovak familial adenomatous polyposis patients.
Neoplasma 2002, 49:356–361.
12. Tulchinsky, Keydar A, Strul H, Goldman G, Klauoner JM, Rabau M:
Extracolonic manifestations of familial adenomatous polyposis after
proctocolectomy. Arch Surg 2005, 140:159–163.
13. Reiner C, Sylcaine O, Waltraut F, Marion M, Cecile B, Thorsten B, Albert A,
Martina K, Gabriela M, Gilles T, Peter P: Familial adenomatous polyposis:
desmoid tumours and lack of ophthalmic lesions (CHRPE) associated
with APC mutations beyond codon 1444. Hum Gene 1994, 4:337–340.
14. Morale SA, Hernandez-Quintela E, Jimenez-Sierra JM, Villalobos JJ, Panduro
A: Congenital hypertrophy of the retinal pigment epithelium associated
with familial adenomatous polyposis. Retina 1994, 14:6–9.
15. Pang CP, Keung JW, Tang NL, Fan DS, Lau JW, Lam DS: Congenital
hypertrophy of the retinal pigment epithelium and APC mutations in
two Chinese families with familial adenomatous polyposis. Eye 2000,
14:18–22.
16. Traboulsi ET, Apostoides J, Giardiello FM, Krush AJ, Booker SV, Hamilton SR,
Maumenee IE: Pigmented ocular fundus lesions and APC mutations in
familial adenomatous polyposis. Ophth Genet 1996, 17:167–174.
17. Anne T, Christine P: Fundus lesions of adenomatous polyposis. Curr Opin
Ophthalmol 1999, 10:168–172.
18. Chen CS, Philips KD, Grist S, Bennet G, Craig JE, Mueck JS, Suthers GK:
Congenital hypertrophy of the retinal pigment epithelium in familial
colorectal cancer. Fam Cancer 2006, 5:397–404.
19. Ziskind A, Kitze MJ, Grobbelaar JJ: The relationship between congenital
hypertrophy of the retinal pigment epithelium (CHRPE) and germline
mutations in the adenomatous polyposis coli (APC) gene. Ophthalmic
Genet 1999, 20:53–56.
20. Romania A, Zakov ZN, MacGannon E, Schroeder T, Heyen F, Jagelman DG:
Congenital hypertrophy of the retinal pigment epithelium in familial
adenomatous polyposis. Ophthalmology 1989, 96:879–884.
Nusliha et al. BMC Research Notes 2014, 7:734 Page 4 of 4
http://www.biomedcentral.com/1756-0500/7/73421. Kanski JJ: Tumours of the eye in Jack J Kanski. 3rd edition. Elsivier: The Text
Book of Clinical ophthalmology; 1994:480–481.
22. Tourino R, Conde-Freire R, Cabezas-Agricola JM, Rodriguez-Aves T, Lopez-
Valladares MJ, Otero-Cepeda JL, Capeans C: Value of the congenital
hypertrophy of the retinal pigment epithelium in the diagnosis of
familial adenomatous polyposis. Int Ophthalmol 2004, 25:101–112.
23. Coleman P, Barnard NA: Congenital hypertrophy of the retinal pigment
epithelium: prevalence and ocular features in the optometric population.
Ophthalmic Physiol Opt 2007, 27:547–555.
24. Tzu JH, Cavuoto KM, Villegas VM, Dubovy SR, Capo H: Optical coherence
tomography findings of pigmented fundus lesions in familial
adenomatous polyposis. Ophthalmic Surg Lasers Imaging Retina 2014,
45(1):69–70.
doi:10.1186/1756-0500-7-734
Cite this article as: Nusliha et al.: Congenital hypertrophy of retinal
pigment epithelium (CHRPE) in patients with familial adenomatous
polyposis (FAP); a polyposis registry experience. BMC Research Notes
2014 7:734.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
